Covered recipient · General Payments record
HOLLY L HAKE HARRIS
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$1,931.99
7 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,715.63 | 4 |
| Food and Beverage | $216.36 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $1,925.63 | 6 |
| PFIZER INC. | $6.36 | 1 |
Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HOLLY L HAKE HARRIS
NPI 1538159207 · CMS profile ID 890706
Allopathic & Osteopathic Physicians / Dermatology
SOUTH BEND, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1538159207?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538159207?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538159207?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538159207?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
7 matching records · $1,931.99 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–7 of 7.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $6.36 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673176171 | CMS |
| Eli Lilly and Company | $135.00 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657859063 | CMS |
| Eli Lilly and Company | $75.00 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657859059 | CMS |
| Eli Lilly and Company | $201.50 | 02/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657859061 | CMS |
| Eli Lilly and Company | $116.50 | 02/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657866057 | CMS |
| Eli Lilly and Company | $547.25 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657848879 | CMS |
| Eli Lilly and Company | $850.38 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657852323 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,042.82 | 1 |
| PY2025 | Principal investigator | $214,389.75 | 98 |
| PY2024 | Recipient | $6,347.66 | 1 |
| PY2024 | Principal investigator | $293,318.73 | 162 |
| PY2023 | Principal investigator | $348,782.35 | 197 |
| PY2022 | Recipient | $100.00 | 2 |
| PY2022 | Principal investigator | $164,469.18 | 81 |
| PY2021 | Principal investigator | $449,676.56 | 73 |
| PY2020 | Recipient | $15,456.30 | 2 |
| PY2020 | Principal investigator | $642,662.67 | 80 |
| PY2019 | Recipient | $418,491.34 | 8 |
| PY2019 | Principal investigator | $1,194,399.32 | 72 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
80 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $1,808.30 | 12/24/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671668431 |
| Principal investigator 1 | AbbVie, Inc. | $923.60 | 12/17/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M16-045 | No dispute reported | 06/30/2026 | 647598807 |
| Principal investigator 1 | AbbVie, Inc. | $5,071.20 | 12/17/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598851 |
| Principal investigator 1 | AbbVie, Inc. | $1,113.10 | 12/17/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598853 |
| Principal investigator 1 | AbbVie, Inc. | $2,929.90 | 12/12/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M16-045 | No dispute reported | 06/30/2026 | 647598809 |
| Principal investigator 1 | AbbVie, Inc. | $305.81 | 12/12/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598855 |
| Principal investigator 1 | PFIZER INC. | $2,236.65 | 12/04/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671676033 |
| Principal investigator 1 | AbbVie, Inc. | $8,100.00 | 11/27/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M16-045 | No dispute reported | 06/30/2026 | 647598811 |
| Principal investigator 1 | AbbVie, Inc. | $2,226.20 | 11/27/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598857 |
| Principal investigator 1 | AbbVie, Inc. | $2,301.60 | 11/26/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598859 |
| Principal investigator 1 | PFIZER INC. | $3,901.95 | 11/23/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671676149 |
| Principal investigator 1 | AbbVie, Inc. | $5,984.90 | 11/13/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M16-045 | No dispute reported | 06/30/2026 | 647598813 |
| Principal investigator 1 | Eli Lilly and Company | $12,797.00 | 11/05/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654297555 |
| Principal investigator 1 | PFIZER INC. | $3,454.10 | 11/05/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671674233 |
| Principal investigator 1 | PFIZER INC. | $14,725.10 | 10/23/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671672629 |
| Principal investigator 1 | AbbVie, Inc. | $4,426.10 | 10/22/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598845 |
| Principal investigator 1 | AbbVie, Inc. | $2,962.00 | 10/22/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598847 |
| Principal investigator 1 | AbbVie, Inc. | $2,144.90 | 10/15/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M16-045 | No dispute reported | 06/30/2026 | 647598805 |
| Principal investigator 1 | AbbVie, Inc. | $834.30 | 10/15/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598849 |
| Principal investigator 1 | AbbVie, Inc. | $9,976.75 | 10/11/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M16-045 | No dispute reported | 06/30/2026 | 647598803 |
| Principal investigator 1 | PFIZER INC. | $499.85 | 09/26/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671669003 |
| Principal investigator 1 | AbbVie, Inc. | $6,350.40 | 09/25/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598839 |
| Principal investigator 1 | AbbVie, Inc. | $1,694.20 | 09/25/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598841 |
| Principal investigator 1 | AbbVie, Inc. | $5,205.65 | 09/09/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M16-045 | No dispute reported | 06/30/2026 | 647598801 |
| Principal investigator 1 | AbbVie, Inc. | $834.30 | 09/05/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598843 |
| Principal investigator 1 | PFIZER INC. | $1,665.30 | 09/04/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671669535 |
| Principal investigator 1 | AbbVie, Inc. | $5,007.20 | 08/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598835 |
| Principal investigator 1 | Eli Lilly and Company | $26,029.00 | 08/27/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY | No dispute reported | 06/30/2026 | 654297325 |
| Principal investigator 1 | Eli Lilly and Company | $72.05 | 08/22/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 654290489 |
| Principal investigator 1 | PFIZER INC. | $1,645.80 | 08/21/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671676865 |
| Principal investigator 1 | PFIZER INC. | $4,838.60 | 08/06/2019 | Non-covered Recipient Entity The South Bend Clinic LLP | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671669125 |
| Principal investigator 1 | AbbVie, Inc. | $420.72 | 08/01/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598837 |
| Principal investigator 1 | AbbVie, Inc. | $6,878.50 | 07/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598829 |
| Principal investigator 1 | AbbVie, Inc. | $2,962.00 | 07/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598831 |
| Principal investigator 1 | AbbVie, Inc. | $1,840.00 | 07/11/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598833 |
| Principal investigator 1 | AbbVie, Inc. | $3,037.40 | 06/27/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598823 |
| Principal investigator 1 | AbbVie, Inc. | $1,343.20 | 06/27/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598825 |
| Principal investigator 1 | AbbVie, Inc. | $308.98 | 06/17/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598827 |
| Principal investigator 1 | Eli Lilly and Company | $14.66 | 06/13/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | No dispute reported | 06/30/2026 | 654293441 |
| Principal investigator 1 | Eli Lilly and Company | $2,044.31 | 06/03/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654290493 |
| Principal investigator 1 | AbbVie, Inc. | $375.00 | 05/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598817 |
| Principal investigator 1 | AbbVie, Inc. | $4,267.50 | 05/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598819 |
| Principal investigator 1 | AbbVie, Inc. | $4,112.80 | 05/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598821 |
| Principal investigator 1 | AbbVie, Inc. | $7,425.80 | 04/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598815 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $76,999.39 | 04/16/2019 | Non-covered Recipient Entity South Bend Clinic Cardiology | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 639754807 |
| Principal investigator 1 | PFIZER INC. | $4,390.31 | 04/16/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC CENTER FOR RESEARCH | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671632287 |
| Principal investigator 1 | PFIZER INC. | $6,300.00 | 04/16/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC CENTER FOR RESEARCH | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671632289 |
| Principal investigator 1 | Eli Lilly and Company | $49,303.46 | 04/15/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654297549 |
| Principal investigator 1 | PFIZER INC. | $70.00 | 04/11/2019 | Non-covered Recipient Entity The South Bend Clinic Center for Research | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671643743 |
| Principal investigator 1 | AbbVie, Inc. | $6,739.10 | 03/28/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598863 |
| Principal investigator 1 | Eli Lilly and Company | $84.15 | 03/14/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654297323 |
| Principal investigator 1 | Eli Lilly and Company | $36.75 | 03/07/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654297551 |
| Principal investigator 1 | AbbVie, Inc. | $7,195.70 | 02/28/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598861 |
| Recipient | Eli Lilly and Company | $1,704.00 | 02/26/2019 | Covered Recipient Physician | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654282355 |
| Recipient | Eli Lilly and Company | $333,525.72 | 02/25/2019 | Covered Recipient Physician | A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654282715 |
| Principal investigator 1 | Eli Lilly and Company | $1,068.09 | 02/25/2019 | Non-covered Recipient Entity COLORADO NEUROLOGICAL INSTITUTE | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654291663 |
| Principal investigator 1 | Eli Lilly and Company | $1,016.46 | 02/25/2019 | Non-covered Recipient Entity ERICKSEN RESEARCH AND DEVELOPMENT LC | A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | No dispute reported | 06/30/2026 | 654293771 |
| Principal investigator 1 | Eli Lilly and Company | $4,492.98 | 02/25/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY | No dispute reported | 06/30/2026 | 654297545 |
| Principal investigator 1 | Eli Lilly and Company | $192,620.00 | 02/12/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654295411 |
| Principal investigator 1 | Eli Lilly and Company | $150,392.00 | 02/05/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 654290487 |
| Principal investigator 1 | Eli Lilly and Company | $22,074.00 | 02/05/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654291511 |
| Principal investigator 1 | Eli Lilly and Company | $15,463.20 | 02/04/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654295413 |
| Principal investigator 1 | Eli Lilly and Company | $400.00 | 01/31/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654294417 |
| Principal investigator 1 | AbbVie, Inc. | $6,184.30 | 01/29/2019 | Non-covered Recipient Entity South Bend Clinic LLP | M15-997 | No dispute reported | 06/30/2026 | 647598865 |
| Principal investigator 1 | Eli Lilly and Company | $19,980.00 | 01/29/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654290491 |
| Principal investigator 1 | Eli Lilly and Company | $45,258.20 | 01/29/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654293443 |
| Principal investigator 1 | Eli Lilly and Company | $223,694.00 | 01/29/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | No dispute reported | 06/30/2026 | 654294415 |
| Principal investigator 1 | Eli Lilly and Company | $165,059.00 | 01/29/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654297543 |
| Principal investigator 1 | Eli Lilly and Company | $3,362.16 | 01/28/2019 | Non-covered Recipient Entity COLORADO NEUROLOGICAL INSTITUTE | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 654290649 |
| Principal investigator 1 | Eli Lilly and Company | $374.19 | 01/28/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654293445 |
| Principal investigator 1 | Eli Lilly and Company | $335.40 | 01/28/2019 | Non-covered Recipient Entity ISLAND NEUROLOGICAL ASSOCIATES PC | MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654293937 |
| Principal investigator 1 | Eli Lilly and Company | $2,061.79 | 01/28/2019 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654295879 |
| Principal investigator 1 | Eli Lilly and Company | $723.29 | 01/28/2019 | Non-covered Recipient Entity SOUTH BEND CLINIC LLP | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654297553 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,624.72 | 01/23/2019 | Non-covered Recipient Entity The South Bend Clinic | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 639759723 |
| Recipient | Eli Lilly and Company | $3,561.00 | 01/22/2019 | Covered Recipient Physician | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 654282713 |
| Recipient | Eli Lilly and Company | $5,874.00 | 01/15/2019 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654282029 |
| Recipient | Eli Lilly and Company | $6,207.00 | 01/08/2019 | Covered Recipient Physician | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654282031 |
| Recipient | Eli Lilly and Company | $37,989.00 | 01/08/2019 | Covered Recipient Physician | A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | No dispute reported | 06/30/2026 | 654282133 |
| Recipient | Eli Lilly and Company | $5,230.62 | 01/08/2019 | Covered Recipient Physician | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654282135 |
| Recipient | Eli Lilly and Company | $24,400.00 | 01/08/2019 | Covered Recipient Physician | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654282353 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $0.00 | 1 |
| PY2025 | Value of interest | $109,356.47 | 1 |
| PY2024 | Amount invested | $2,443.72 | 1 |
| PY2024 | Value of interest | $109,356.47 | 1 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $106,912.75 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $154,320.92 | 1 |
| PY2021 | Amount invested | $0.00 | 1 |
| PY2021 | Value of interest | $88,340.48 | 1 |
| PY2020 | Amount invested | $0.00 | 1 |
| PY2020 | Value of interest | $80,642.76 | 1 |
| PY2019 | Amount invested | $80,595.00 | 1 |
| PY2019 | Value of interest | $806,985.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
7 records · PY2019–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | Digital Diagnostics Inc. | $0.00 | $109,356.47 | Shares Owned by Immediate Family (Ben Clark) | Immediate family member | No dispute reported | 06/30/2026 | 1254605365 |
| PY2024 | Digital Diagnostics Inc. | $2,443.72 | $109,356.47 | Shares Owned by Immediate Family | Immediate family member | No dispute reported | 06/30/2026 | 1153967797 |
| PY2023 | Digital Diagnostics Inc. | $0.00 | $106,912.75 | Shares Owned by Immediate Family | Immediate family member | No dispute reported | 06/30/2026 | 1060331987 |
| PY2022 | Digital Diagnostics Inc. | $0.00 | $154,320.92 | Shares Owned by Immediate Family | Immediate family member | No dispute reported | 06/30/2026 | 961154523 |
| PY2021 | Digital Diagnostics Inc. | $0.00 | $88,340.48 | Shares Owned by Immediate Family | Immediate family member | No dispute reported | 06/30/2026 | 855625849 |
| PY2020 | Digital Diagnostics Inc. | $0.00 | $80,642.76 | Shares Owned by Immediate Family | Immediate family member | No dispute reported | 06/30/2026 | 737170185 |
| PY2019 | IDx Technologies Inc. | $80,595.00 | $806,985.00 | Shares Owned by Immediate Family | Immediate family member | No dispute reported | 06/30/2026 | 676471935 |